Hydroxocobalamin for treatment of catecholamine-resistant vasoplegia during liver transplantation: A single-center series of 20 cases. Int J Surg Case Rep 2022 Sep;98:107488
Date
08/19/2022Pubmed ID
35981485Pubmed Central ID
PMC9399471DOI
10.1016/j.ijscr.2022.107488Scopus ID
2-s2.0-85135893802 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
INTRODUCTION: Catecholamine-resistant vasoplegia is a potentially devastating complication during liver transplantation. Hydroxocobalamin has emerged as a treatment for vasoplegia associated with cardiac surgery, liver transplantation, and septic shock.
PRESENTATION OF CASE: We performed a retrospective review of patients who underwent liver transplantation between October 2015 and May 2020 to evaluate the efficiency of hydroxocobalamin in this setting.
DISCUSSION: A total of 137 patients underwent liver transplantation, of which 20 received hydroxocobalamin for vasoplegia. Administration of hydroxocobalamin increased mean arterial pressure and reduced vasoactive drug requirements.
CONCLUSION: This case series adds to the previous individual reports describing the use of hydroxocobalamin during liver transplantation suggesting hydroxocobalamin can mitigate refractory hypotension from catecholamine resistant vasoplegia during liver transplantation.
Author List
Boettcher BT, Woehlck HJ, Makker H, Pagel PS, Freed JKAuthors
Brent Boettcher DO Associate Professor in the Anesthesiology department at Medical College of WisconsinJulie K. Freed MD, PhD Vice Chair, Associate Professor in the Anesthesiology department at Medical College of Wisconsin
Hemanckur Makker MD Assistant Professor in the Anesthesiology department at Medical College of Wisconsin
Harvey J. Woehlck MD Professor in the Anesthesiology department at Medical College of Wisconsin
